Shots: Silence to receive $20M up front, $10M as research milestone for SLN500 + for each of the two optioned assets, ~$663M including clinical, regulatory and commercial milestones and royalties […]readmore
Tags : Complement-Mediated Diseases
Shots: Ionis to get $75M upfront plus $684M as development, regulatory, sales milestones, license fees and to receive tiered royalties up to 20% on sales. Ionis will be responsible for […]readmore